Overview

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
0
Participant gender:
All
Summary
We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bryon Adinoff
University of Texas Southwestern Medical Center
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Lidocaine
Polystyrene sulfonic acid
Criteria
Inclusion Criteria:

- 25-60 years old

- men or women

- any race or ethnicity

- cocaine addition is primary present and lifetime drug of abuse

- live locally

Exclusion Criteria:

- Patients with active DSM (Diagnostic Statistical Manual)-IV other Substance Dependence
(except nicotine) within the previous three months, Affective Disorder, Schizophrenic
Disorders.

- significant cognitive impairment (WTAR<70) (Wechsler Test of Adult Reading <70)..

- use of tricyclic anti-depressants, benzodiazepines, cimetidine, mood stabilizers,
opioids, lithium, sympathomimetics, anticonvulsants, sedative/hypnotics, β-blockers,
or dopamine agonists will be excluded from the study.

- Medical conditions that might limit cooperation (e.g. dementia) or put the patient at
medical risk (i.e. significant hematologic, hepatic, renal, or cardiovascular
pathology - particularly arrhythmias) will be excluded.

- Patients with congenital or idiopathic methemoglobinemia or patients taking
medications associated with increased risk of methemoglobinemia (including
sulfonamides, acetaminophen, acetanilid, aniline dyes, benzocaine, chloroquine,
dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin,
nitroprusside, pamaquine, paraaminosalicylic acid, phenacetin, phenobarbital,
phenytoin, primaquine, quinine) will be excluded.

- Patients with past or present neurologic disorders (i.e. severe head trauma, transient
ischemic attacks, stroke, tumor, etc.) will be excluded. - Active suicidal ideation,
pregnant or nursing women, and prisoners will be excluded from the study.